About this trial
Recurrent pregnancy losses (RPL) are characterized by the occurrence of more than one spontaneous pregnancy loss. It is caused by different known factors, but about half of the cases remain without an explanation. Efforts are being done in the scientific community to solve this cases. In this study, the investigators aim to investigate genetic factors that might predispose to RPL, as well as the influence of the uterine microbiota (microorganisms that normally live in the uterus of women).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
RPL group: history of at least two spontaneous pregnancy losses, regardless of whether they have living children, and whose etiology for the pregnancy losses was not determined by the care team's protocols;
Control group: at least two full-term pregnancies and no history of difficulty getting pregnant, pregnancy loss or other infertility factors.
Disqualifiers
RPL group: less than two spontaneous pregnancy losses and those with a known cause for repeated pregnancy losses;
Control group: N/A
Trial population
Women who seek the Gynecology and Obstetrics Service of the Hospital de Clínicas de Porto Alegre (HCPA) for care and investigation of causes of infertility or for exams not related to this condition will be included in the study.
Trial design
Case-control
Retrospective
Treatments tested in this trial
Exome test
Diagnostic testAn exome will be performed on the participants of RPL group.
Microbiota analysis
Diagnostic testA cervical microbiota analysis will be performed in the RPL and control groups.
Treatment groups
Trial outcomes
Primary outcomes
Microbiome
The participants microbiome will be evaluated aiming to compare the species profile between cases and controls. The bacteria present in the microbiome will be described at the genus and species level.
Exome
The participants exomes will be evaluated to look for variants in specific genes, aiming to identify rare variants that will be compared with frequencies from population genomic databases. The impact of the identified variants on proteins will be assessed through in silico functional predictors.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Hospital de Clinicas de Porto Alegre
Lead sponsor
Federal University of Rio Grande do Sul
Collaborator